Successful inhibition of spermatogenesis in man without loss of libido: A potential new approach to male contraception

Abstract

Marked reduction of sperm count occurred in eight fertile men bearing subdermal Silastic capsules containing testosterone who received 50 mg of either norgestrienone or R 2323 twice weekly per OS. Four other men also bearing testosterone implants who received an equivalent dose of norethindrone have not shown a similar drop in sperm count. None of the patients who received either norgestrienone or R 2323 reported loss of libido or potency. These results suggest one of these nor-steroids may be used for a male contraceptive pill.